Cargando…
Novel knock‐in mouse model for the evaluation of the therapeutic efficacy and toxicity of human podoplanin–targeting agents
Podoplanin is a key molecule for enhancing tumor‐induced platelet aggregation. Podoplanin interacts with CLEC‐2 on platelets via PLatelet Aggregation–inducing domains (PLAGs). Among our generated antibodies, those targeting the fourth PLAG domain (PLAG4) strongly suppress podoplanin–CLEC‐2 binding a...
Autores principales: | Ukaji, Takao, Takemoto, Ai, Shibata, Harumi, Kakino, Mamoru, Takagi, Satoshi, Katayama, Ryohei, Fujita, Naoya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8177788/ https://www.ncbi.nlm.nih.gov/pubmed/33735501 http://dx.doi.org/10.1111/cas.14891 |
Ejemplares similares
-
A safety study of newly generated anti-podoplanin-neutralizing antibody in cynomolgus monkey (Macaca fascicularis)
por: Ukaji, Takao, et al.
Publicado: (2018) -
Targeting Podoplanin for the Treatment of Osteosarcoma
por: Takemoto, Ai, et al.
Publicado: (2022) -
Targeting a novel domain in podoplanin for inhibiting platelet-mediated tumor metastasis
por: Sekiguchi, Takaya, et al.
Publicado: (2015) -
Platelet-activating factor podoplanin: from discovery to drug development
por: Takemoto, Ai, et al.
Publicado: (2017) -
A critical role of platelet TGF-β release in podoplanin-mediated tumour invasion and metastasis
por: Takemoto, Ai, et al.
Publicado: (2017)